NCT07939919
A Study of AK158D1 in Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Dose Limiting Toxicities (DLTs)
Timeframe: At the end of Cycle 1 (each cycle is 21 days)
Adverse Events (AEs)
Timeframe: Up to approximately 2 years
Secondary (8)
Pharmacokinetics (PK) Characteristics
Anti-Drug Antibodies (ADA)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DoR)
Show 3 moreShow less
Time to Response (TTR)
Progression Free Survival (PFS)
Overall Survival (OS)
Arms and interventions
AK158D1Experimental
Drugs: AK158D1
Sites
2 sites in 1 country